Lacrimal function and ocular complications in patients treated with systemic isotretinoin.
OBJECTIVE
To evaluate the effect on lacrimal function and ocular complications in patients with severe acne vulgaris during systemic treatment with 13-cis-retinoic acid (isotretinoin).


METHODS
Forty patients with acne vulgaris were treated with systemic isotretinoin at dosages of 0.5-1 mg/kg per day for two months. Full ophthalmologic examination, Schirmer I test, fluorescein break-up (BUT) and microbiological investigations of the conjunctival flora were done before, during the second month and at least one month after the end of the treatment.


RESULTS
The average Schirmer values before and after the treatment were 21.6 mm/5 minutes (SD +/- 7.01) and 18.48 mm/5 minutes (SD +/- 7.87) respectively. After the treatment BUT was less than 10 seconds in 50% of the patients and 55% had blepharitis. Subjective symptoms like dryness, itching and contact lens intolerance occurred in 42.5% and colonization of the conjunctiva by Staphylococcus aureus increased significantly during treatment (p= 0.031). All abnormal findings disappeared one month after the cessation of treatment.


CONCLUSIONS
Isotretinoin causes signs and symptoms of dry eye, probably by reducing meibomian gland function, but ocular complications are generally not serious when low doses are used for a limited time, and are reversible after discontinuation.
Bozkurt
B
B
Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey.
Irkeç
M T
MT
Atakan
N
N
Orhan
M
M
Geyik
P O
PO
D000152:Acne Vulgaris / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D001762:Blepharitis / Q000139:chemically induced / Q000503:physiopathology; D003229:Conjunctival Diseases / Q000139:chemically induced / Q000382:microbiology / Q000503:physiopathology; D015352:Dry Eye Syndromes / Q000139:chemically induced / Q000503:physiopathology; D005128:Eye Diseases / Q000139:chemically induced* / Q000382:microbiology / Q000503:physiopathology; D015818:Eye Infections, Bacterial / Q000139:chemically induced / Q000382:microbiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D007765:Lacrimal Apparatus / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000139:chemically induced / Q000382:microbiology / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000302:isolation & purification
D015474:Isotretinoin